PMID- 23845449
OWN - NLM
STAT- MEDLINE
DCOM- 20140303
LR  - 20220419
IS  - 1479-6821 (Electronic)
IS  - 1351-0088 (Linking)
VI  - 20
IP  - 5
DP  - 2013 Oct
TI  - Are G3 ENETS neuroendocrine neoplasms heterogeneous?
PG  - 649-57
LID - 10.1530/ERC-13-0027 [doi]
AB  - The new WHO classification of gastroenteropancreatic (GEP) neuroendocrine tumors 
      (NET) implies that G3 neoplasms with mitotic index >20 and/or Ki67 index >20% are 
      neuroendocrine carcinomas (NEC), described as poorly differentiated, small or 
      large cell types, by analogy with lung NEC. To characterize the subgroup of 
      non-small-cell-type GEP and thoracic NET with mitotic index >20 and/or Ki67 >20% 
      according to their pathological features, response to cisplatin and overall 
      survival (OS). We reviewed pathological and clinical presentation of G3 
      non-small-cell-type NET referred to our institution for 5 years. Data from 166 
      patients with metastatic thoracic and GEP-NET were collected. Twenty-eight 
      patients (17%) fulfill the inclusion criteria. Tumors were classified as 
      well-differentiated NET (G3-WDNET) in 42.8% of cases and poorly differentiated, 
      large-cell NEC (G3-LCNEC) in 57.2% of cases. Plasma chromogranin A or 
      neuron-specific enolase were elevated in 42 and 25% respectively of G3-WDNET and 
      31 and 50% of G3-LCNEC. Somatostatin receptor scintigraphy was positive in 88 and 
      50% of G3-WDNET or G3-LCNEC respectively. Complete or partial response to 
      cisplatin was observed in 31% of cases, all classified as G3-LCNEC. The median OS 
      was 41 months for G3-WDNET but 17 months for G3-LCNEC (P=0.34). Short survival 
      was observed in 25% of G3-WDNET but 62.5% of G3-LCNEC patients (P=0.049). G3 
      ENETS GEP and thoracic neuroendocrine neoplasms (NEN) could constitute a 
      heterogeneous subgroup of NEN as regards diagnosis, prognosis, and treatment. If 
      confirmed, future classifications may consider splitting them into two groups 
      according to their morphological differentiation.
FAU - Velayoudom-Cephise, Fritz-Line
AU  - Velayoudom-Cephise FL
AD  - Department of Nuclear Medicine and Endocrine Oncology, Villejuif, France.
FAU - Duvillard, Pierre
AU  - Duvillard P
FAU - Foucan, Lydia
AU  - Foucan L
FAU - Hadoux, Julien
AU  - Hadoux J
FAU - Chougnet, Cecile N
AU  - Chougnet CN
FAU - Leboulleux, Sophie
AU  - Leboulleux S
FAU - Malka, David
AU  - Malka D
FAU - Guigay, Joel
AU  - Guigay J
FAU - Goere, Diane
AU  - Goere D
FAU - Debaere, Thierry
AU  - Debaere T
FAU - Caramella, Caroline
AU  - Caramella C
FAU - Schlumberger, Martin
AU  - Schlumberger M
FAU - Planchard, David
AU  - Planchard D
FAU - Elias, Dominique
AU  - Elias D
FAU - Ducreux, Michel
AU  - Ducreux M
FAU - Scoazec, Jean-Yves
AU  - Scoazec JY
FAU - Baudin, Eric
AU  - Baudin E
LA  - eng
PT  - Journal Article
DEP - 20130819
PL  - England
TA  - Endocr Relat Cancer
JT  - Endocrine-related cancer
JID - 9436481
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Chromogranin A)
RN  - 0 (SYP protein, human)
RN  - 0 (Synaptophysin)
RN  - EC 4.2.1.11 (Phosphopyruvate Hydratase)
RN  - Q20Q21Q62J (Cisplatin)
RN  - Gastro-enteropancreatic neuroendocrine tumor
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antineoplastic Agents/therapeutic use
MH  - Chromogranin A/metabolism
MH  - Cisplatin/therapeutic use
MH  - Female
MH  - Humans
MH  - Intestinal Neoplasms/drug therapy/metabolism/*pathology
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Grading
MH  - Neuroendocrine Tumors/drug therapy/metabolism/*pathology
MH  - Pancreatic Neoplasms/drug therapy/metabolism/*pathology
MH  - Phosphopyruvate Hydratase/metabolism
MH  - Stomach Neoplasms/drug therapy/metabolism/*pathology
MH  - Synaptophysin/metabolism
OTO - NOTNLM
OT  - Ki67 index
OT  - WHO classification
OT  - grade 3 neuroendocrine carcinoma
OT  - mitotic count
EDAT- 2013/07/13 06:00
MHDA- 2014/03/04 06:00
CRDT- 2013/07/13 06:00
PHST- 2013/07/13 06:00 [entrez]
PHST- 2013/07/13 06:00 [pubmed]
PHST- 2014/03/04 06:00 [medline]
AID - ERC-13-0027 [pii]
AID - 10.1530/ERC-13-0027 [doi]
PST - epublish
SO  - Endocr Relat Cancer. 2013 Aug 19;20(5):649-57. doi: 10.1530/ERC-13-0027. Print 
      2013 Oct.